
Approvals granted for the treatment of Fragile X Syndrome
Kaerus Bioscience’s lead candidate KER-0193 has been granted both Orphan Drug Designation and Rare Pediatric Drug Designations for the treatment of Fragile X syndrome (FXS) by the US Food and Drugs Administration (FDA). This follows the recent successful completion of a Phase I trial of KER-0193 in healthy volunteers, which… Read More
